When I researching Ancestry today, I came across two (2) articles – Ancestry.com Sued for ‘Misleading’ Data Handling Claims(Radio): https://www.bloomberg.com/news/audio/2019-04-26/ancestry-com-sued-for-misleading-data-handling-claims-radio (audio file; about 2:18 minutes long) and Ancestry Is Said to Prepare for IPO as DNA-Test Industry Booms: https://www.bloomberg.com/news/articles/2019-04-18/ancestry-com-is-said-to-prepare-ipo-as-dna-test-industry-booms.
For the first link above Ancestry.com Sued for ‘Misleading’ Data Handling Claims(Radio): https://www.bloomberg.com/news/audio/2019-04-26/ancestry-com-sued-for-misleading-data-handling-claims-radio, here’s the gist:
A new lawsuit alleges that genealogy information provider Ancestry.com has a “longstanding practice” of failing to get sufficient informed consent agreements from customers who submit medical and DNA information. Ancestry says the lawsuit is without merit. Bloomberg Law’s Sara Merken shares details of the lawsuit with Nancy Lyons in the Bloomberg 99.1 Washington newsroom.
For the second link,Ancestry Is Said to Prepare for IPO as DNA-Test Industry Booms: https://www.bloomberg.com/news/articles/2019-04-18/ancestry-com-is-said-to-prepare-ipo-as-dna-test-industry-booms, here’s a brief synopsis:
Ancestry.com LLC is readying an initial public offering, according to people familiar with the matter, preparing to take advantage of growing consumer interest in DNA tests and investors’ appetite for new health and technology stocks.
An IPO of the Lehi, Utah-based company could take place in the second half of the year, according to the people, who asked not to be identified because the matter is private.
A representative for Ancestry declined to comment.
The market for genetic tests is rapidly expanding on two main fronts: Consumers want to know more about their health and heritage, and health companies see potential in the vast troves of genetic data harvested from the tests. Direct-to-consumer DNA testing sales have grown from about $15 million in 2010 to more than $99 million in 2017, and are projected to reach $310 million by 2022, according to market-research company Kalorama Information.
While it may reach $310 million by 2022, it may not. What has been consistent has been the reduction in test prices. When I considered DNA testing back in 2011, the price for autosomal DNA testing at FamilyTree DNA (FTDNA) and 23andMe was $199. Now, FTDNA and MyHeritageDNA have lowered their price to $79. AncestryDNA, 23andMe, and most of the other DNA testing companies have kept their regular prices at $99. However, all of them lower their sale prices to $49 (couple of times a year), $59, $69, $79, or $89.